Invictus RG acquired a new stake in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,175 shares of the medical research company’s stock, valued at approximately $394,000.
A number of other large investors have also recently added to or reduced their stakes in PRAH. Dimensional Fund Advisors LP increased its stake in PRA Health Sciences by 61.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 295,974 shares of the medical research company’s stock valued at $19,306,000 after purchasing an additional 113,074 shares in the last quarter. Aperio Group LLC purchased a new stake in shares of PRA Health Sciences during the 2nd quarter valued at about $233,000. Strs Ohio boosted its holdings in shares of PRA Health Sciences by 17.8% during the 2nd quarter. Strs Ohio now owns 18,500 shares of the medical research company’s stock valued at $1,387,000 after acquiring an additional 2,800 shares during the last quarter. CAPROCK Group Inc. purchased a new stake in shares of PRA Health Sciences during the 2nd quarter valued at about $208,000. Finally, Sei Investments Co. boosted its holdings in shares of PRA Health Sciences by 4.9% during the 2nd quarter. Sei Investments Co. now owns 14,654 shares of the medical research company’s stock valued at $1,100,000 after acquiring an additional 690 shares during the last quarter. Institutional investors and hedge funds own 98.49% of the company’s stock.
PRA Health Sciences, Inc. (PRAH) opened at $81.00 on Wednesday. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38. The stock has a market cap of $5,186.81, a P/E ratio of 30.09, a P/E/G ratio of 1.42 and a beta of 0.40. PRA Health Sciences, Inc. has a 1-year low of $52.76 and a 1-year high of $84.38.
A number of analysts have recently issued reports on the stock. SunTrust Banks reaffirmed a “buy” rating on shares of PRA Health Sciences in a report on Wednesday, August 9th. Credit Suisse Group raised their price target on shares of PRA Health Sciences from $80.00 to $84.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Robert W. Baird raised their price target on shares of PRA Health Sciences from $82.00 to $83.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Citigroup reaffirmed a “buy” rating and set a $93.00 price target (up previously from $90.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. Finally, Mizuho set a $87.00 price target on shares of PRA Health Sciences and gave the company a “buy” rating in a report on Friday, December 1st. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $89.09.
In related news, Director Matthew P. Young sold 5,115 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 2.10% of the company’s stock.
WARNING: “Invictus RG Acquires Shares of 5,175 PRA Health Sciences, Inc. (PRAH)” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/06/invictus-rg-acquires-shares-of-5175-pra-health-sciences-inc-prah.html.
PRA Health Sciences Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.